CoChat

Pharmacological Properties of Glutamatergic Drugs Targeting NMDA Receptors and their Application in Major Depression

Serafini, Gianluca, Pompili, Maurizio, Innamorati, Marco, Dwivedi, Yogesh, Brahmachari, Goutam, Girardi, Paolo · 2013 · Current Pharmaceutical Design
Cited by 78

The DOI matches its Crossref record.

Abstract

BACKGROUND: A growing body of evidence suggests that glutamatergic system, especially the abnormalities of glutamate and N-methyl-D-aspartate (NMDA) receptors contribute to the pathophysiology of major depressive disorders. An imbalance in glutamatergic neurotransmission may contribute to increased levels of NMDA agonism, thereby enhancing excitatory activity in most brain circuits involved in major depression. Although NMDA receptor antagonists have been demonstrated to possess antidepressant-like activity, the molecular changes underlying abnormal glutamatergic signaling still remain poorly understood. Therefore, we aimed to review the current literature focusing on the main pharmacological properties and the impact of glutamatergic drugs targeting NMDA receptors in major depression. METHODS: A detailed literature search in PubMed/Medline and ScienceDirect databases using the terms glutamate, depression and major depressive disorder has been performed. RESULTS: Most drugs acting at glutamatergic receptors showed biochemical effects indicative of antidepressant activity in both clinical and preclinical studies. Recent neuroimaging and genetic contributions also confirm the antidepressant properties of these medications. However, human studies including NMDA receptor antagonists provided mixed results. In overall, glutamatergic receptor modulation may facilitate neuronal stem cell enhancement (neurogenesis) as well as the release of neurotransmitters associated with treatment response to depression in humans. LIMITATIONS: Cognitive side effects and psychotomimetic properties complicate the application and the development of clinically useful agents. CONCLUSIONS: Glutamatergic system represents a target for effective intervention in major depression. Specifically, those glutamatergic medications targeting NMDA receptors by inhibiting the release of neurotransmitters or modulating its post-synaptic responses may serve as molecule modulators with specific antidepressant properties.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/13816128113199990293

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 78

Metadata

Authors
Serafini, G., Pompili, M., Innamorati, M., Dwivedi, Y., Brahmachari, G., & Girardi, P.
Venue
Current Pharmaceutical Design
Published
2013-01-18
Volume
19
Issue
10
Pages
1898-1922
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2160011621
Cited by
78
References
0
FWCI
6.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Properties of Glutamatergic Drugs Targeting NMDA Receptors and their Application in Major Depression. https://app.cochat.ai/papers/10.2174/13816128113199990293
The paper
Serafini, G., Pompili, M., Innamorati, M., Dwivedi, Y., Brahmachari, G., & Girardi, P. (2013). Pharmacological Properties of Glutamatergic Drugs Targeting NMDA Receptors and their Application in Major Depression. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990293

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.